Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

Phase 1 Withdrawn Hengenix Biotech Inc Sanyou Biopharmaceuticals(Shanghai)Co., Ltd · collab Shanghai ZJ Bio-Tech Co., Ltd · collab

RandomizedSequentialQuadruple-blindOther

Summary

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

Timeline

Start: 2020-12-09
Primary completion: 2021-09-06
Completion: 2021-09-18

Outcome

Outcome not reported

Stopped (Business): “Sponsor strategy”

Publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HLX70	Monoclonal antibody	3 mg/kg	Intravenous
Subject	HLX70	Monoclonal antibody	10 mg/kg	Intravenous
Subject	HLX70	Monoclonal antibody	30 mg/kg	Intravenous